Results 151 to 160 of about 2,742,410 (287)

Discovery of circadian clock activators with anti-obesity efficacy via suppression of adipocyte development and hypertrophy. [PDF]

Mol Ther
Xiong X, Pangemanan J, Kiperman T, Fang Z, Agua A, Huang W, Horne D, Ma K.   +7 more
europepmc   +1 more source

Long‐Term Risk of Rheumatoid Arthritis in Individuals With Autism Spectrum Disorder: A Population‐Based Matched Cohort Study

Autism Research, EarlyView.
ABSTRACT To investigate the long‐term risk of rheumatoid arthritis (RA) among individuals with autism spectrum disorder (ASD), addressing potential immune comorbidity in ASD populations. A population‐based matched cohort was assembled using Swedish registers, including 46,164 individuals diagnosed with ASD between 1987 and 2017, matched to 4,634,895 ...
Evora Hailin Zhu, Stephen Z. Levine, Matilda Morin, Weiyao Yin, Benjamin Christofferson, Johan Askling, Natalia Rivera, Abraham Reichenberg, Joseph D. Buxbaum, Sven Sandin, Benjamin Hon Kei Yip   +10 more
wiley   +1 more source

Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure. [PDF]

Int J Mol Sci
Nicze M, Borówka M, Dec A, Bułdak Ł, Bołdys A, Okopień B.   +5 more
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Comparative genomics reveals immunomodulatory and anti-obesity traits of Lactococcus lactis subsp. lactis. [PDF]

Appl Microbiol Biotechnol
Jeong H, Choi H, Park YS.
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Acute anti-obesity treatment with celastrol reduces body weight, cerebral inflammation and metabolic imbalances in mice. [PDF]

Mol Med
Ferreiro A, Holgado M, González-Alday R, González-Soto S, Fernandez-Sevilla LM, Vicente Á, López-Larrubia P, Lizarbe B.   +7 more
europepmc   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

OBESITY 2011 Abstract Supplement

, 2012

core  

Anti-obesity medication use sparks effort-based sanctions and social penalties. [PDF]

Sci Rep
Tissot TT, Roth LHO.
europepmc   +1 more source